Stock Scorecard



Stock Summary for Madrigal Pharmaceuticals Inc (MDGL) - $317.09 as of 11/20/2024 8:25:11 PM EST

Total Score

7 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MDGL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MDGL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MDGL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MDGL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MDGL (52 out of 90)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for MDGL

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance 11/11/2024 12:47:00 PM
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More 11/10/2024 2:30:00 PM
5 Small Drug Stocks to Buy as Trump Gets Re-Elected 11/8/2024 12:18:00 PM
Check Out What Whales Are Doing With MDGL - Madrigal Pharmaceuticals ( NASDAQ:MDGL ) 11/4/2024 6:15:00 PM
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up 11/1/2024 1:42:00 PM
This High-Flying Stock Just Became a Better Buy 10/31/2024 9:45:00 AM
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ ( resmetirom ) Abstracts in NASH/MASH at the AASLD Liver Meeting® - Madrigal Pharmaceuticals ( NASDAQ:MDGL ) 10/30/2024 12:00:00 PM
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ ( resmetirom ) Abstracts in NASH/MASH at the AASLD Liver Meeting® 10/30/2024 12:00:00 PM
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings? 10/21/2024 1:03:00 PM
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis 10/21/2024 12:00:00 PM

Financial Details for MDGL

Company Overview

Ticker MDGL
Company Name Madrigal Pharmaceuticals Inc
Country USA
Description Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 317.09
Price 4 Years Ago 111.17
Last Day Price Updated 11/20/2024 8:25:11 PM EST
Last Day Volume 277,156
Average Daily Volume 528,195
52-Week High 368.29
52-Week Low 168.25
Last Price to 52 Week Low 88.46%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -10.74
Free Cash Flow Ratio 6.89
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 5.98
Total Cash Per Share 46.02
Book Value Per Share Most Recent Quarter 35.64
Price to Book Ratio 8.10
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 81.94
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 21,810,400
Market Capitalization 6,915,859,736
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 10.80%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -26.49%
Reported EPS 12 Trailing Months -25.02
Reported EPS Past Year -19.40
Reported EPS Prior Year -19.94
Net Income Twelve Trailing Months -518,670,000
Net Income Past Year -373,600,000
Net Income Prior Year -295,350,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months -1.87

Balance Sheet

Total Cash Most Recent Quarter 1,003,627,000
Total Cash Past Year 634,131,000
Total Cash Prior Year 358,774,000
Net Cash Position Most Recent Quarter 886,540,000
Net Cash Position Past Year 518,651,000
Long Term Debt Past Year 115,480,000
Long Term Debt Prior Year 69,675,000
Total Debt Most Recent Quarter 117,087,000
Equity to Debt Ratio Past Year 0.78
Equity to Debt Ratio Most Recent Quarter 0.87
Total Stockholder Equity Past Year 405,333,000
Total Stockholder Equity Prior Year 197,389,000
Total Stockholder Equity Most Recent Quarter 777,155,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -438,322,000
Free Cash Flow Per Share Twelve Trailing Months -20.10
Free Cash Flow Past Year -325,709,000
Free Cash Flow Prior Year -225,074,000

Options

Put/Call Ratio 0.52
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 32.20
MACD Signal 26.12
20-Day Bollinger Lower Band 180.46
20-Day Bollinger Middle Band 257.47
20-Day Bollinger Upper Band 334.48
Beta -0.47
RSI 61.07
50-Day SMA 242.42
150-Day SMA 182.01
200-Day SMA 161.78

System

Modified 11/19/2024 6:27:27 AM EST